The global In Vitro Diagnostics market size was valued at USD 83.2 billion in 2020 and is projected to expand at a CAGR of 4.5% from 2021 to 2027. The growth may be due to increased adoption of in vitro diagnostics. (IVD) Due to the increase in testing due to the pandemic. The development of automated in vitro diagnostic systems for laboratories and hospitals to provide efficient, accurate and error-free diagnosis is expected to drive market growth. The market’s profitable growth rate is also increasing as the number of in vitro diagnostic products released by major players increases.
A full report of In Vitro Diagnostics Market available at https://www.orionmarketreports.com/ivd-in-vitro-diagnostics-market/37814/
In Vitro Diagnostics Market: Segmentation
By Product & Service
• Reagents
• Instruments
• Software and Services
By Technique
• Immunodiagnostics
• Hematology
• Molecular Diagnostics
• Tissue Diagnostics
• Clinical Chemistry
• Others
By Application
• Infectious Diseases
• Cancer
• Cardiac Diseases
• Immune System Disorders
• Nephrological Diseases
• Gastrointestinal Diseases
• Others
By End User
• Standalone Laboratories
• Hospitals
• Academic & Medical Schools
• Point-of-Care
• Others
Company Profiles
• F. Hoffmann-la Roche Ltd.
• Danaher
• Abbott
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.
• BD
• Biomérieux SA
• Bio-Rad Laboratories, INC.
• Qiagen
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
